4//SEC Filing
McCormac Paul 4
Accession 0001209191-23-054910
CIK 0001907108other
Filed
Nov 8, 7:00 PM ET
Accepted
Nov 9, 8:35 PM ET
Size
7.3 KB
Accession
0001209191-23-054910
Insider Transaction Report
Form 4
McCormac Paul
Chief Technical Officer
Transactions
- Conversion
Series B convertible preferred stock
2023-11-07−29,061→ 0 total→ Common Stock (3,191 underlying) - Conversion
Common Stock
2023-11-07+3,191→ 17,349 total
Footnotes (1)
- [F1]Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date.
Documents
Issuer
Lexeo Therapeutics, Inc.
CIK 0001907108
Entity typeother
Related Parties
1- filerCIK 0001994981
Filing Metadata
- Form type
- 4
- Filed
- Nov 8, 7:00 PM ET
- Accepted
- Nov 9, 8:35 PM ET
- Size
- 7.3 KB